Aleva has proprietary techniques for Target Specific Stimulation enabling a new class of neuromodulation therapies that should be both more clinically effective and more cost effective. Devices designed specifically for brain targets will be both precise - able to monitor and stimulate individual neuron populations - and adaptive - able to adjust to the individual patient.
Our products will:
• Improve Current Procedures
directSTIM reduces surgery times, side effects, and re-operations. It delivers better clinical outcomes and reduces the total cost of care. spiderSTIM helps neurosurgeons make faster and more informed decisions, leading to better clinical outcomes in patients.
• Expand the Existing Market
DBS is still seen as a therapy of last resort because of the risks associated with the surgery.
directSTIM improves the safety and certainty of the procedure in Parkinsonʼs patients and will increase adoption of DBS by the medical community.
spiderSTIM significantly reduces difficulties with the procedure, and therefore increases the number of patients that can be indicated for DBS therapy.
• Enable New Indications
Our next generation products can find and stimulate difficult to reach areas of the brain and provide unique capabilities with respect to feedback-modulated stimulation. This translates directly to the development of novel therapies for indications not currently served by neurostimulation, or drugs. spiderSTIM can access even the smallest brain targets.
ALEVA NEUROTHERAPEUTICS SA | EPFL INNOVATION PARK - BUILDING D | 1015 LAUSANNE | SWITZERLAND | INFO@ALEVA-NEURO.COM
|CONTACT & DIRECTIONS|